Since then, there has been a rapidly-expanding evidence base in HR+/HER2– breast cancer, including PFS and OS results and analyses of efficacy in specific patient populations, like those with early relapse or visceral metastases. The gene discussed is ERBB2; the disease is breast carcinoma.